Association Analysis of Polymorphisms with Aspirin-Exacerbated Respiratory Disease in a Korean Population by Jin Sol Lee, Joon Seol Bae, Byung-Lae Park, Hyun Sub Cheong, Jeong-Hyun Kim, Jason Yongha Kim, Suhg Namgoong, Ji-On Kim, Choon-Sik Park, Hyoung Doo Shin

Subjects: Get full text

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy by Sara Cherradi, Salomé Roux, Marie Dupuy, Séverine Tabone-Eglinger, Edouard Tuaillon, Marianne Ziol, Eric Assenat, Hong Tuan Duong

Subjects: Get full text

Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report by Jialin Qian, Tianqing Chu

Subjects: Get full text

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis o... by Kei Sonehara, Kazunari Tateishi, Kiyotaka Yoh, Kazuhiro Usui, Yukio Hosomi, Kazuma Kishi, Go Naka, Kageaki Watanabe, Shu Tamano, Kohei Uemura, Hideo Kunitoh

Subjects: Get full text

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial by Xiaoyang Hong, Yongjian Guo, Wenbo Shi, Kangshun Zhu, Licong Liang, Liteng Lin, Ye Chen, Jingwen Zhou, Jingjun Huang, Jiabai Huang, Yaozhu Wu, Wensou Huang, Mingyue Cai

Subjects: Get full text

Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia by Abhishek Abhishek, Jonathan A Cook, Helen M Parry, Anne Francis, Lelia Duley, Vicki S Barber, Paul Moss, Nicholas Peckham

“…This study aims to determine in patients with chronic lymphocytic leukaemia (CLL) if a 3-week pause in Bruton tyrosine kinase inhibitor therapy (BTKi) starting 1 week before delivery of SARS-CoV-2 vaccine booster, improves vaccine immune response when compared with continuation of BTKi.Methods and analysis An open-label, randomised controlled superiority trial will be conducted in haematology clinics in approximately 10 UK National Health Service (NHS) hospitals. …”
Get full text

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada by Lara Chayab, Natasha B. Leighl, Mina Tadrous, Christine M. Warren, William W. L. Wong

Get full text

The improved prognosis of <i>FLT3</i>-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data by Matthew Schwede, Gladys Rodriguez, Vanessa E. Kennedy, Solomon Henry, Douglas Wood, Gabriel N. Mannis, Ravindra Majeti, Jonathan H. Chen, Eran Bendavid, Tian Yi Zhang

Get full text

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer? by Tommaso Porcelli, Cristina Luongo, Anna Cerbone, Carmine Di Luccio, Mariantonia Nacchio, Maria Angela De Stefano, Martin Schlumberger, Domenico Salvatore

Subjects: Get full text

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors by Russell J. Schilder, Drew Rasco, Manish R. Sharma

Subjects: Get full text

Gastrointestinal stromal tumors mimicking as gynecological tumors-A case series by Kiran Trivedi, Shabnam Toppo, Apoorwa Sharma, Rohit Kumar Jha, Binit Bharati, Pushpanjali, Tulika Sinha

Subjects: Get full text

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients by Piyada Sitthideatphaiboon, Pronwasun Simseekeaw, Chinachote Teerapakpinyo, Nicha Zungsontiporn, Wariya Chintanapakdee, Itthi Itthisawatpan, Shanop Shuangshoti, Virote Sriuranpong, Thanisa Tongbai, Chanida Vinayanuwattikun

Subjects: Get full text

Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analys... by Zhonghua Zhao, Xiongying Jiang, Shiping Wen, Yanzhang Hao

Subjects: Get full text

Emerging targeted therapies in oral oncology: Focus on EGFR inhibition by Vishnu Priya Veeraraghavan, Shikhar Daniel, Arun Kumar Dasari, Kaladhar Reddy Aileni, Chaitra patil, Santosh R. Patil

Subjects: Get full text

Screening and identification of host signaling pathways for alleviating influenza-induced production of pro-inflammatory cytokines, IP-10, IL-8, and MCP-1, using a U937 cell-based... by Si Chen, Si Chen, Yang Yu, Yue Su, Xiaoqin Lian, Lefang Jiang, Zhuogang Li, Mingxin Zhang, Yarou Gao, Haonan Zhang, Xingjian Zhu, Jiaxin Ke, Xulin Chen

Subjects: Get full text

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy by Anna De Lucia, Lucia Mazzotti, Lucia Mazzotti, Anna Gaimari, Anna Gaimari, Matteo Zurlo, Roberta Maltoni, Claudio Cerchione, Sara Bravaccini, Angelo Delmonte, Lucio Crinò, Patricia Borges de Souza, Luigi Pasini, Fabio Nicolini, Fabrizio Bianchi, Manel Juan, Hugo Calderon, Chiara Magnoni, Chiara Magnoni, Luca Gazzola, Luca Gazzola, Paola Ulivi, Massimiliano Mazza

Subjects: Get full text

Exploring the inhibitory effect and mechanism of isorhamnetin therapy on oral squamous cell carcinoma based on network pharmacology and molecular docking by YU Fangfang, ZHOU Jingjing, YANG Jie, QU Huijuan, HUI Guangyan

Subjects: “…isorhamnetin|oral squamous cell carcinoma|pi3k/akt signaling pathway|src tyrosine kinase|estrogen receptor-1|network pharmacology|molecular docking|experimental verification <i>in vitro</i>…”
Get full text

JAK inhibitors: a new choice for diabetes mellitus? by Mengjun Zhou, Qi Shen, Bo Li

“…Abstract Altered tyrosine kinase signaling is associated with a variety of diseases. …”
Get full text

Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation by Stephen E. Langabeer, Stuart Macleod, Úna Bhreathnach, Kamal Fadalla

“…Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). …”
Get full text

Overview of Prognosis of FLT3 Mutations and Interactions with Other Genetic Alterations in Acute Myeloid Leukemia by Ayşe Gül Bayrak Tokaç, Aynur Dağlar Aday

“…In this letter, we emphasized the prognostic importance of a crucial biomarker in acute myeloid leukemia (AML) – the Fms - like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase that plays a significant role in several cellular signalling processes. …”
Get full text